PL2293804T3 - Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania - Google Patents
Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowaniaInfo
- Publication number
- PL2293804T3 PL2293804T3 PL08789969T PL08789969T PL2293804T3 PL 2293804 T3 PL2293804 T3 PL 2293804T3 PL 08789969 T PL08789969 T PL 08789969T PL 08789969 T PL08789969 T PL 08789969T PL 2293804 T3 PL2293804 T3 PL 2293804T3
- Authority
- PL
- Poland
- Prior art keywords
- hsv
- preparation
- herpes simplex
- simplex virus
- modified tropism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2008/000358 WO2009144755A1 (en) | 2008-05-29 | 2008-05-29 | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
EP08789969.6A EP2293804B1 (en) | 2008-05-29 | 2008-05-29 | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2293804T3 true PL2293804T3 (pl) | 2014-03-31 |
Family
ID=40032777
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL08789969T PL2293804T3 (pl) | 2008-05-29 | 2008-05-29 | Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania |
PL13168599T PL2700405T3 (pl) | 2008-05-29 | 2008-05-29 | Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego wykorzystanie i proces przygotowania |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13168599T PL2700405T3 (pl) | 2008-05-29 | 2008-05-29 | Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego wykorzystanie i proces przygotowania |
Country Status (11)
Country | Link |
---|---|
US (2) | US9157071B2 (pl) |
EP (2) | EP2293804B1 (pl) |
JP (1) | JP5683455B2 (pl) |
AU (1) | AU2008357065B2 (pl) |
DK (2) | DK2700405T3 (pl) |
ES (2) | ES2667622T3 (pl) |
HU (1) | HUE037311T2 (pl) |
NO (1) | NO2700405T3 (pl) |
PL (2) | PL2293804T3 (pl) |
PT (2) | PT2293804E (pl) |
WO (1) | WO2009144755A1 (pl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
MX2016005488A (es) | 2013-10-28 | 2016-10-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vector hsv oncolitico. |
DK3256570T3 (da) | 2015-02-11 | 2021-06-14 | Univ Bologna Alma Mater Studiorum | Retargeteret herpesvirus med en glycoprotein H-fusion |
MX2018009126A (es) | 2016-01-27 | 2019-08-21 | Oncorus Inc | Vectores virales oncoliticos y usos de estos. |
AU2017276726B2 (en) * | 2016-06-09 | 2023-09-21 | Alma Mater Studiorum Universita Di Bologna | Herpesvirus with modified glycoprotein D |
CN109563490A (zh) * | 2016-06-09 | 2019-04-02 | 大学之母博洛尼亚大学 | 具有经修饰的糖蛋白b的疱疹病毒 |
MX2019000252A (es) | 2016-06-30 | 2019-10-09 | Oncorus Inc | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. |
GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
CA3070299A1 (en) | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
EP3677592A4 (en) * | 2017-08-30 | 2021-06-09 | KM Biologics Co., Ltd. | MODIFIED HSV GD PROTEIN AND VACCINE CONTAINING IT |
EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
EP3887529A4 (en) * | 2018-11-28 | 2022-08-31 | The Brigham & Women's Hospital, Inc. | NEXT GENERATION REGULABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE |
WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
CN112501137B (zh) * | 2020-11-11 | 2023-10-20 | 深圳先进技术研究院 | 一种神经环路标记系统 |
CN113969287B (zh) * | 2021-10-22 | 2024-05-28 | 中国科学院深圳先进技术研究院 | 重组单纯疱疹病毒的亲和筛选细胞系及其构建方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
WO1998033914A1 (en) | 1997-01-31 | 1998-08-06 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US6080399A (en) | 1998-04-23 | 2000-06-27 | Arch Development Corporation | Vaccine adjuvants for immunotherapy of melanoma |
US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
ES2309167T3 (es) | 2001-02-19 | 2008-12-16 | Merck Patent Gmbh | Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida. |
WO2002096460A1 (en) | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
US20040115688A1 (en) | 2002-04-19 | 2004-06-17 | Cheung Irene Y. | Detection of gd2 synthase mrna and uses thereof |
US20070243170A1 (en) * | 2002-10-07 | 2007-10-18 | The University Of Chicago | Targeting of Herpes Simplex Virus to Specific Receptors |
AU2003282691A1 (en) | 2002-10-07 | 2004-05-04 | University Of Chicago | Targeting of herpes simplex virus to specific receptors |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
AU2006304804B2 (en) | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
US20080003202A1 (en) | 2006-03-28 | 2008-01-03 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
EP2423305A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
GB0714578D0 (en) * | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
-
2008
- 2008-05-29 PT PT87899696T patent/PT2293804E/pt unknown
- 2008-05-29 PL PL08789969T patent/PL2293804T3/pl unknown
- 2008-05-29 ES ES13168599.2T patent/ES2667622T3/es active Active
- 2008-05-29 PT PT131685992T patent/PT2700405T/pt unknown
- 2008-05-29 EP EP08789969.6A patent/EP2293804B1/en active Active
- 2008-05-29 EP EP13168599.2A patent/EP2700405B1/en not_active Not-in-force
- 2008-05-29 AU AU2008357065A patent/AU2008357065B2/en not_active Ceased
- 2008-05-29 ES ES08789969T patent/ES2425489T3/es active Active
- 2008-05-29 JP JP2011511172A patent/JP5683455B2/ja active Active
- 2008-05-29 HU HUE13168599A patent/HUE037311T2/hu unknown
- 2008-05-29 WO PCT/IT2008/000358 patent/WO2009144755A1/en active Application Filing
- 2008-05-29 DK DK13168599.2T patent/DK2700405T3/en active
- 2008-05-29 NO NO13168599A patent/NO2700405T3/no unknown
- 2008-05-29 PL PL13168599T patent/PL2700405T3/pl unknown
- 2008-05-29 DK DK08789969.6T patent/DK2293804T3/da active
-
2010
- 2010-11-24 US US12/953,528 patent/US9157071B2/en active Active
-
2015
- 2015-09-24 US US14/864,098 patent/US9744199B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK2293804T3 (da) | 2013-08-26 |
ES2425489T3 (es) | 2013-10-15 |
EP2700405A1 (en) | 2014-02-26 |
AU2008357065B2 (en) | 2013-07-25 |
US20160074448A1 (en) | 2016-03-17 |
WO2009144755A1 (en) | 2009-12-03 |
AU2008357065A1 (en) | 2009-12-03 |
US9157071B2 (en) | 2015-10-13 |
PT2700405T (pt) | 2018-05-02 |
PT2293804E (pt) | 2013-08-29 |
DK2700405T3 (en) | 2018-05-22 |
ES2667622T3 (es) | 2018-05-11 |
PL2700405T3 (pl) | 2018-08-31 |
EP2293804A1 (en) | 2011-03-16 |
JP2011522532A (ja) | 2011-08-04 |
US9744199B2 (en) | 2017-08-29 |
NO2700405T3 (pl) | 2018-09-01 |
US20110318268A1 (en) | 2011-12-29 |
HUE037311T2 (hu) | 2018-08-28 |
EP2700405B1 (en) | 2018-04-04 |
EP2293804B1 (en) | 2013-05-22 |
JP5683455B2 (ja) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE037311T2 (hu) | Módosított tropizmusú herpes simplex vírus (HSV), alkalmazásai és eljárás az elõállítására | |
HRP20182194T1 (hr) | Onkolitički herpes simpleks virus i njegova terapeutska uporaba | |
GB2446721B (en) | Herpes simplex viruses and methods of viral replication | |
IL216508A (en) | Vaccines against herpes simplex virus type 1 and / or 2 and their preparations and uses | |
HK1200332A1 (en) | Highly concentrated drug particles, formulations, suspensions and uses thereof | |
ZA201007630B (en) | Stable natural color process, products and use thereof | |
EP2501723A4 (en) | HEPATITIS B-VIRUS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF | |
EP2307033A4 (en) | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS | |
HRP20160573T1 (hr) | Herpes simplex virusna cjepiva | |
EP2576581A4 (en) | RECOMBINANT RNA VIRUSES AND USES THEREOF | |
IL224935A (en) | By sugarcane cilia virus and its use in the study of plant genome function | |
EP2460878A4 (en) | VARICELLA VIRUS WITH ORF7 LACK, VACCIN VIRUS AND USE THEREOF | |
ZA201303254B (en) | Small viral rna molecules and uses thereof | |
EP2473629B8 (fr) | Identification du tropisme cellulaire de virus | |
EP2340844A4 (en) | AVIAN INFLUENZA ANTI-VIRUS AGENT AND PRODUCT COMPRISING AVIAN INFLUENZA ANTI-VIRUS AGENT | |
AU2006292131A8 (en) | Systems for detection and production of respiratory, herpes and enteric viruses | |
AU2010904623A0 (en) | Small viral RNA molecules and uses thereof | |
GB0809073D0 (en) | Infection of cells by herpes simplex virus | |
GB0712770D0 (en) | Anti-Koi herpes virus molecules | |
GB0708941D0 (en) | Infection of cells by herpes simplex virus | |
GB0609381D0 (en) | Treatment using herpes simplex virus | |
AU2007903674A0 (en) | Epitopes of Herpes Simplex virus | |
GB0609384D0 (en) | Infection of cells by herpes simplex virus | |
AU2010903478A0 (en) | Modified Hepatitis C Virus Proteins |